Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 2010  |  Volume : 31  |  Issue : 1  |  Page : 8-17

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?

1 Department of Medical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India
2 Department of Surgical Oncology, Terna Sahyadri Hospital, Nerul, Navi Mumbai, India

Correspondence Address:
Nirmal V Raut
18/144, Anand Nagar, Santacruz (East), Mumbai - 400 055
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-5851.68846

Rights and Permissions

Neoadjuvant chemotherapy (NACT) in breast cancer has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. Many questions are still lurking in the minds of oncologists treating breast cancer. This review analyzes the evidence from metaanlyses, major multiinstitutional prospective trials, retrospective institutional series and systematic reviews in breast cancer to determine the current standards and controversies in NACT. The most effective drugs, their advantages, issues and controversies in delivery as well as the criteria for response are reviewed. A summary of evidence-based consensus is presented and unresolved aspects are discussed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded740    
    Comments [Add]    
    Cited by others 1    

Recommend this journal